Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on May 30, 2007
Japanese Journal of Clinical Oncology 2007 37(5):382-384; doi:10.1093/jjco/hym037
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
37/5/382    most recent
hym037v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kim, S. J.
Right arrow Articles by Kim, B. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kim, S. J.
Right arrow Articles by Kim, B. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© 2007 Foundation for Promotion of Cancer Research

Combination Chemotherapy with Bortezomib, Cyclophosphamide and Dexamethasone may be Effective for Plasma Cell Leukemia

Seok Jin Kim1, Jeeyong Kim2, Yunjung Cho2, Bo Kyoung Seo3 and Byung Soo Kim1,

1 Division of Hematology and Oncology, Department of Internal Medicine
2 Department of Laboratory Medicine
3 Department of Diagnostic Radiology, Korea University Medical Center, Seoul, Korea

For reprints and all correspondence: Byung Soo Kim, Division of Oncology and Hematology, Department of Internal Medicine, Korea University Medical Center, 126-1, Anamdong 5-ga, Seongbuk-ku, Seoul, 136-705, Korea. E-mail: kbs0309{at}korea.ac.kr

Received November 10, 2006; accepted December 23, 2006

Plasma cell leukemia is a rare malignant plasma cell disorder characterized by proliferation of plasma cells in blood and the bone marrow, the outcome of which is poor with conventional therapy. More effective treatment strategies are therefore needed for this disorder. Here, we report a case of secondary plasma cell leukemia from Immunoglobulin D multiple myeloma refractory to doxorubicin-containing chemotherapy and thalidomide. The patient achieved complete remission with bortezomib-containing chemotherapy as follows: bortezomib 1.3 mg/m2 intravenous infusion on days 1, 4, 8 and 11; cyclophosphamide 750 mg/m2 intravenous infusion on days 1 and 3; dexamethasone 40 mg/m2 intravenous infusion on days 1–4. Complete remission was maintained until the fourth course of the treatment, and we then performed autologous peripheral blood stem cell transplantation. Our experience suggests that combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be an effective induction treatment for plasma cell leukemia.

Key Words: bortezomib • cyclophosphamide • plasma cell leukemia • multiple myeloma


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.